Floatz logo

BUSULFANUM

Primary Effusion Lymphoma

City of Hope Medical CenterSmall moleculePhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

18 Active assets in the Primary Effusion Lymphoma cohort.

Asset / SponsorPhaseRating
Vincristine sulfate
National Cancer Institute (NCI)
Phase 2BBB
Etoposide
National Cancer Institute (NCI)
Phase 2BBB
Cyclophosphamide
National Cancer Institute (NCI)
Phase 2BB
Adriamycin
National Cancer Institute (NCI)
Phase 2BB
Prednisone
National Cancer Institute (NCI)
Phase 2BB

View all 38 →

Same molecule, other indications

BUSULFANUM is also rated in:

myelodysplastic/myeloproliferative neoplasmActive
BBB
Indicative · Phase 2/3
76 / 100
View asset →
graft versus host diseaseActive
BBB
Indicative · Phase 4
74 / 100
View asset →
disease related to hematopoietic stem cell transplantActive
BBB
Indicative · Phase 3
74 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →